OneMedNet Corp - Class A Common Stock (ONMD)

MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(b)(2) (the “Rule”) after the market value of the Company’s common stock exceeded $35,000,000 for 10 consecutive business days. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming compliance with the Rule.   As a result, the Company has cleared all listing deficiency notices issued by Nasdaq.

MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) after the closing bid price of the Company’s common stock was $1.00 per share or greater for 10 consecutive business days. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming compliance with the Rule.

MINNEAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that the Company regained compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) based on the filing of its periodic reports on Form 10-Q for the fiscal quarters ended March 31, June 30 and September 30, 2024. The Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming compliance with the Rule.

MINNEAPOLIS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), a Real-World Data (RWD) platform — has announced its collaboration with Bayer's AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products.

MINNEAPOLIS, Nov. 27, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (“iRWD™”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced the Company received an expected notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the Company’s failure to timely file its Form 10-Q for the fiscal quarter ended September 30, 2024 (the “New Delinquent Filing”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC.

MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), a pioneer in curating regulatory-grade Real World Data (RWD) including electronic health records, laboratory results, and medical imaging, has announced an additional strategic investment in Bitcoin. This investment is designed to enhance the company's financial resilience and support the expansion of its cutting-edge iRWD™ platform. As of November 12, 2024, the Company has invested in approximately 34 Bitcoin.

MINNEAPOLIS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (RWD), is pleased to announce a strategic refresh of its Board of Directors following the successful transition to a publicly traded entity. This move reinforces our commitment to dynamic leadership and active engagement as we accelerate growth in this new phase.

MINNEAPOLIS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that it has entered into a securities purchase agreement with an affiliate of Off the Chain Capital (collectively, “Off the Chain”) in a follow-on private placement that resulted in gross proceeds of approximately $1.7 million, before deducting fees and expenses payable by the Company. OneMedNet previously consummated a private placement with Off the Chain Capital on July 24, 2024 that resulted in gross proceeds of $2.7 million.

MINNEAPOLIS, Sept. 12, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data ("RWD"), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced the Company received an expected notice (the “First Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the Company’s failure to timely file its Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC.

MINNEAPOLIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (RWD), has announced that Bob Golden has joined the OneMedNet Executive Team as Chief Financial Officer spearheading all aspects of the company’s financial and accounting operations while continuing to serve as a member of the Board of Directors.

MINNEAPOLIS, Aug. 09, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (RWD), has successfully integrated its proprietary AI technology into its data curation process, ensuring rapid and precise de-identification of patient data. This innovation, coupled with other changes undertaken by the Company, has significantly reduced OneMedNet’s operational costs, enabling the company to process vast amounts of clinical data in minutes rather than hours. Additionally, OneMedNet can now deliver longitudinal clinical data and images to Life Science organizations up to five times faster than before, as measured from the end-to-end data curation process, significantly expediting delivery.

OneMedNet (NASDAQ: ONMD, ONMDW), the leading curator of regulatory-grade Imaging Real World Data (“iRWD”) through its proven OneMedNet iRWD(TM) solution, has entered into a standby equity purchase agreement (“SEPA”) with YA II PN, Ltd, a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global, LP. According to the forms filed with the U.S. Security and Exchange Commission, OneMedNet the option to sell to Yorkville up to $25 million of the company’s shares of common stock, par value $0.0001 per share “at the company’s request from time to time following both the repayment of the promissory note. . . and the effectiveness of a resale registration statement covering the shares of issued under the SEPA. The SEPA terminates on its 24-month anniversary.” The company also paid a $25,000 structuring fee to Yorkville and agreed to pay a commitment fee of $500,000 to Yorkville; that payment will be paid in shares in two tranches. EF Hutton served as exclusive placement agent on the transaction. EF Hutton served as exclusive placement agent on the $1.5 million private placement.

- Regains compliance with Nasdaq minimum closing bid price rule -

Partner’s software products and services are utilized by hundreds of life science organizations, including the top 30 biopharmaceutical companies

Secures new life science company customer through this globally recognized and trusted new channel

Intelligent Bio Solutions Inc. (NASDAQINBS), a medical technology company, offers rapid, intelligent, and non-invasive testing solutions. On May 29, the company announced its success in recruiting and starting the screening of subjects for its pharmacokinetic (PK) study. This study is a crucial step in Intelligent Bio Solutions' FDA 510(k) regulatory clearance process. The dedicated team worked diligently to ensure the study's design met FDA standards.

OneMedNet’s new iRWD™ platform customer impacts more than 150 million patients each year

MINNEAPOLIS, May 23, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (“RWD”), inclusive of electronic health records, laboratory results and medical imaging, is pleased to announce a greater than five (5)-fold expansion of its proprietary iRWD™ network and platform.

OneMedNet (NASDAQONMD) is the leading curator of regulatory-grade Real World Data (“iRWD(TM)”) through its proven OneMedNet iRWD(TM) solution. The company recently announced that it has entered into a definitive securities purchase agreement, dated as of March 28, 2024, with an institutional investor providing up to $4.54 million in funding through a private placement for the issuance of senior convertible notes. OneMedNet intends to use the net proceeds from the offering for working capital purposes. “This securities purchase agreement demonstrates confidence in our comprehensive iRWD(TM) platform, marking an important milestone for OneMedNet as we have the investment needed to expedite our growth, enhance our network, and propel the development of our AI-driven solutions. Our platform is designed to meet the clinical requirements necessary across various domains, including but not limited to rare diseases, oncology and cardiology. We are committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of our strategy to enhance patient outcomes and pave the next wave of healthcare innovation,” said Aaron Green, president and CEO of OneMedNet.

Cash Infusion Provides Significant Cash Runway of Up to $4.54 Million

~ President, Aaron Green, Assumes Role of Chief Executive Officer ~

~ Partnership Will Significantly Expand Depth and Diversity of Real World Data Availability for Life Science Innovation ~

Several stocks are currently undergoing noteworthy developments, making them worthy of closer monitoring. This feature will delve into five stocks that merit inclusion in watch lists, offering insight into their potential.

MINNEAPOLIS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“iRWD”), is receiving an enthusiastic response from attendees at the 15th Annual SCOPE Summit.

MINNEAPOLIS, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“RWD”), today announced a growth initiative supporting women’s health research. The company is seeing increasing business and new opportunities from Life Science innovators including leading pharmaceutical companies requiring RWD for women’s health programs and has already filled multiple orders.